Want to see WGS full AI Analyst Report?
WGS Stock Chart & Stats
$90.28
$1.44(2.44%)
At close: 4:00 PM EDT
$90.28
$1.44(2.44%)
Day’s Range― - ―
52-Week Range$32.21 - $170.87
Previous Close$60.5
Volume611.52K
Average Volume (3M)742.59K
Market Cap
$1.98B
Enterprise Value$2.07B
Total Cash (Recent Filing)$132.55M
Total Debt (Recent Filing)$167.40M
Price to Earnings (P/E)―
Beta0.94
Next Earnings
Nov 03, 2026EPS Estimate
0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.64
Shares Outstanding29,822,540
10 Day Avg. Volume689,260
30 Day Avg. Volume742,589
Financial Highlights & Ratios
PEG Ratio2.86
Price to Book (P/B)11.35
Price to Sales (P/S)8.18
P/FCF Ratio245.23
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue4.57
Enterprise Value/Gross Profit6.69
Enterprise Value/Ebitda-27.14
Forecast
1Y Price Target
$88.50Price Target Upside-1.97% Downside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.1
Revenue Forecast (FY)$482.27M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginStrong revenue expansion alongside gross margins near 70% indicates meaningful demand and attractive test economics. If maintained, this combination can support reinvestment, absorb operating costs, and provide a foundation for durable profitability as volume scales.
Payer Coverage ExpansionBroader payer coverage improves the addressable reimbursable market for GeneDx’s testing services and can reduce access barriers for providers. The expansion also creates a durable opportunity to convert clinical demand into revenue, provided collection execution improves.
Liquidity And Cost ActionsCompleted cost actions should help moderate the expense base, while approximately $188M of pro forma liquidity provides greater capacity to fund laboratory operations and strategic initiatives. This financial flexibility can support execution while the company works toward sustained profitability.
Bears Say
Negative Cash GenerationThe reversal to substantial operating and free cash burn weakens earnings quality and increases reliance on available liquidity or external capital. Continued cash consumption could constrain investment choices and raise financial risk unless profitability and working-capital conversion improve.
Low Collection RatesLow claims collection means reported test volumes are not translating into equivalent realized revenue, limiting the economic benefit of growth. The year-over-year deterioration and delayed improvement create persistent reimbursement execution risk over the next several quarters.
Genome Cost And Revenue PressureHigher genome unit costs can pressure margins and cash generation as genome volumes expand, especially when reimbursement collection remains incomplete. Management expects costs to stay broadly flat in H2 2026, so the burden may persist before anticipated 2027 efficiencies.
GeneDx Holdings News
WGS FAQ
What was GeneDx Holdings’s price range in the past 12 months?
GeneDx Holdings lowest stock price was $32.21 and its highest was $170.87 in the past 12 months.
What is GeneDx Holdings’s market cap?
GeneDx Holdings’s market cap is $1.98B.
When is GeneDx Holdings’s upcoming earnings report date?
GeneDx Holdings’s upcoming earnings report date is Nov 03, 2026 which is in 14 days.
How were GeneDx Holdings’s earnings last quarter?
GeneDx Holdings released its earnings results on Aug 03, 2026. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.188 by $0.198.
Is GeneDx Holdings overvalued?
According to Wall Street analysts GeneDx Holdings’s price is currently Overvalued.
Does GeneDx Holdings pay dividends?
GeneDx Holdings does not currently pay dividends.
What is GeneDx Holdings’s EPS estimate?
GeneDx Holdings’s EPS estimate is 0.07.
How many shares outstanding does GeneDx Holdings have?
GeneDx Holdings has 29,822,540 shares outstanding.
What happened to GeneDx Holdings’s price movement after its last earnings report?
GeneDx Holdings reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.188. Following the earnings report the stock price went up 4.48%.
Which hedge fund is a major shareholder of GeneDx Holdings?
Currently, no hedge funds are holding shares in WGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
GeneDx Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.50 (-1.97% Downside)
$88.50 (-1.97% Downside)
Blogger Sentiment
Bullish
WGS Sentiment 86%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 7.7%
Last 30 Days ▼ 7.7%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-46.28%
12-Months-Change
Fundamentals
Return on Equity
-38.72%
Trailing 12-Months
Asset Growth
3.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
GeneDx Holdings
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
WGS Company Deck
WGS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reflects a cautiously optimistic outlook: strong operational performance (record test volumes, revenue growth, return to profitability, margin improvement, and major payer coverage wins) provides clear highlights, while significant near‑term challenges remain around low outpatient collection rates, higher genome unit costs, and timing lags for revenue realization. Management presented a concrete multi‑pronged plan (RCM, payer workflows, technology, commercial investments) and reinforced guidance, expecting meaningful RCM and revenue uplift beginning in Q4 2026 and more substantially in 2027.View all WGS earnings summariesWGS Revenue Breakdown
96.59% Diagnostic test revenue
3.41% Other
WGS Stock 12 Month Forecast
Average Price Target
$88.50
▼(-1.97% Downside)
Technical Analysis
Ownership Overview
46.38% Insiders
18.82% Mutual Funds
2.50% Other Institutional Investors
14.82% Public Companies and
Individual Investors